Raised inflammation markers on blood tests
Potential benefit studied: Changes in selected inflammatory blood markers
Positive human evidencePooled randomized-trial evidence shows that curcumin lowers C-reactive protein (CRP), a blood marker of inflammation. A 2024 review of 103 trials rated the certainty of this finding high, while a 66-trial review reported lower CRP, TNF-alpha and IL-6.
A 2024 systematic review covered 103 randomised trials and 7,216 participants across 42 outcomes. A 2023 review pooled 66 randomised trials examining inflammatory and oxidative-stress markers. The reviews include different populations, formulations, doses and study durations, and some underlying trials may overlap.
This is strong ingredient-level support for a CRP effect in studied populations. Longevity itself has not been clinically tested for this outcome; the final extract specification must be established before comparing its dose with the trials. CRP reduction does not prove better daily performance or longer life.
The doses above describe research, not personal dosing instructions. Ingredient studies do not diagnose symptoms or establish medical suitability. Discuss medicines, existing conditions and treatment decisions with an appropriate healthcare professional.